ClinicalTrials.Veeva

Menu
A

Advanced Clinical Research Institute | Tampa, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Risankizumab
ABBV-157
EVO756
ANB019
Cedirogant
EP262
Imsidolimab
Dupilumab
Lutikizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 15 total trials

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria

This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism...

Enrolling
Chronic Inducible Urticaria
Drug: Oral EVO756

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There...

Active, not recruiting
Psoriasis
Drug: Ustekinumab
Drug: Risankizumab

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Invitation-only
Vitiligo
Drug: Upadacitinib
Drug: Placebo

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling
Hidradenitis Suppurativa
Drug: Lutikizumab
Drug: Placebo

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Enrolling
Moderate Plaque Psoriasis
Drug: Risankizumab
Drug: Deucravacitinib

This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and...

Active, not recruiting
Chronic Inducible Urticaria
Drug: Oral EP262

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urtica...

Enrolling
Chronic Spontaneous Urticaria
Drug: Placebo
Drug: Oral EP262

The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe...

Active, not recruiting
Atopic Dermatitis
Biological: Placebo
Biological: OpSCF

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This...

Invitation-only
Psoriasis
Drug: Risankizumab

Trial sponsors

AbbVie logo
E
AnaptysBio logo
E
O
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems